David Arkowitz - 27 Apr 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role: Chief Financial Officer
Signature: /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Issuer symbol: MCRB
Transactions as of: 27 Apr 2023
Transactions value $: $0
Form type: 4
Filing time: 01 May 2023, 16:43:22 UTC
Previous filing: 14 Apr 2023
Next filing: 31 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MCRB	Common stock	Award	$0	+42.5K	+34.24%	$0.00	167K	27 Apr 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 42,500 shares.
F2	Includes 11,121 shares of common stock acquired under the Issuer's employee stock purchase plan.

Content

On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 42,500 shares.

Includes 11,121 shares of common stock acquired under the Issuer's employee stock purchase plan.